viewRhinomed Ltd

Rhinomed wins FDA approval for nasal dilator


Rhinomed's (ASX:RNO) sport technology the Turbine was granted registration with the US Food and Drug Administration as a medical device.

The Turbine™ is an internal nasal dilator that increases airflow by an average of 38% and can assist athletes as a solution to breathlessness during aerobic exercise.

A recent independent high performance product trial was carried out by former Olympic Cyclist, Rob Crowe, which showed that 66% of professional riders increasing their power output at an average of 6.5%.

Successfully granting US FDA registration of the Turbine is an important step in allowing the Turbine™ to enter the giant US market with premium positioning as a FDA class 1 medical device in the US.

The Turbine is currently sold on line and at selected retail outlets in Australia.

Registration granted to the Turbine by the US FDA allows the company to have a much wider range of discussions with US based retailers and wholesalers.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: Rhinomed Ltd

Price: 0.076 AUD

Market: ASX
Market Cap: $12.86 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Tiziana Life Sciences: Dr Weiner announces 'completely novel' approach to...

Harvard Medical School's Dr Howard Weiner, who's also chairman of Tiziana Life Sciences' (LON:TILS)(NASDAQ:TLSA) scientific advisory board, speaks to Proactive London's Andrew Scott after winning a competitive research grant from the NIH (National Institutes of Health) to investigate the drug's...

3 hours, 40 minutes ago

2 min read